Loading
Loading
Research Overview
Melanocortin MC4R agonist; activates central nervous system melanocortin pathways in the hypothalamus to initiate sexual arousal independent of vascular mechanisms, unlike PDE5 inhibitors. First FDA-approved treatment for HSDD.
Overview
PT-141 (bremelanotide) is a synthetic cyclic peptide that functions as a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. It was derived from Melanotan-II through structural modification and has been studied in preclinical settings for its central nervous system melanocortin receptor engagement, particularly at MC3R and MC4R subtypes expressed in hypothalamic and limbic brain regions associated with sexual behaviour regulation.
In preclinical behavioural neuroscience research, PT-141 has been studied in animal models examining melanocortin-regulated aspects of sexual behaviour. Rodent model studies have used standardised sexual behaviour paradigms to characterise how central melanocortin receptor agonism by PT-141 influences behavioural endpoints in laboratory settings.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pt-141 (bremelanotide) melanocortin has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Melanocortin MC4R agonist; activates central nervous system melanocortin pathways in the hypothalamus to initiate sexual arousal independent of vascular mechanisms, unlike PDE5 inhibitors. First FDA-approved treatment for HSDD.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
